
Opinion|Videos|July 12, 2024
MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024
Dr Garfall, MD, provides further insights around the MajesTEC-1 study.
Advertisement
Video content above is prompted by the following:
- Please provide your key takeaways from this study. How do these updated results impact the potential use of teclistamab in the management of RRMM?
- What is the value of long-term follow-up data in multiple myeloma? How does this impact treatment regimens?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
3
Most Medicare Beneficiaries Find Plan Shopping Confusing, Survey Finds
4
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
5